
|Articles|October 20, 2015
Efficacy of Ozurdex in DME in the real world clinical setting-Leowenstein interview
Professor Anat Lowenstein talks about the impact of Ozurdex in treating diabetic macular edema (DME) in the real world clinical setting. This renowned expert in the DME field, explores what the licensing of Ozurdex in DME means to both patients and retinal specialists when treating this potentially blinding condition.
Advertisement
Redirect to video article
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA guidance to help accelerate cell and gene therapies
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
The Residency Report: Cardiovascular risk scores as a window into ocular disease
4
Outlook Therapeutics resubmits BLA for bevacizumab-vikg (ONS-5010/LYTENAVA)
5





















